Liposomal amphotericin B (AmBisome®) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: A pooled analysis

Mycoses

Volumn 50, Issue 3, 2007, Pages 205-209

  Cordonnier, C ^a   Bresnik, M ^b   Ebrahimi, R ^b  

^a HENRI MONDOR HOSPITAL   (France)

^b GILEAD SCIENCES   (United States)

Author keywords

AmBisome; Amphotericin B; Aspergillosis

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HUMAN; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL;

ADOLESCENT; ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; LIPOSOMES; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 34247598891     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2007.01362.x     Document Type: Article

References (14)

1. Ellis D. Amphotericin B: spectrum and resistance. J Antimicrob Chemother 2002 49 (Suppl. 1 7 10.
2. Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999 340 : 764 71.
3. Leenders AC, Daenen S, Jansen RL et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998 103 : 205 12.
4. Ellis M, Spence D, de Pauw B et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998 27 : 1406 12.
5. Walsh TJ, Goodman JL, Pappas P et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001 45 : 3487 96.
6. Ringdén O, Meunier F, Tollemar J et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991 28 : 73 82.
7. Tollemar J, Ringdén O. Early pharmacokinetic and clinical results from a noncomparative multicentre trial of amphotericin B encapsulated in a small unilamellar liposome (AmBisome®). Drug Invest 1992 4 : 232 8.
8. Mills W, Chopra R, Linch DC, Goldstone AH. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol 1994 86 : 754 60.
9. Ng TT, Denning DW. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data. Arch Intern Med 1995 155 : 1093 8.
10. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002 34 : 7 14.
11. Cornely OA, Maertens J, Bresnik M, Herbrecht R. Liposomal amphotericin B (L-AMB) as initial therapy for invasive filamentous fungal infections (IFFI): a randomized, prospective trial of a high loading regimen vs. standard dosing (AmBiLoad Trial). Blood 2005 106 : 900a (abstract 3222).
12. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002 347 : 408 15.
13. Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002 34 : 563 71.
14. Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004 39 : 1563 71.